

“EXPRESS MAIL” Mailing Label NO: EL719362924US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent application of	: Group Art Unit: Not Yet Assigned
	Donald L. Siegel	:
Appln. No:	Not Yet Assigned	: Examiner: Not Yet Assigned
Filed:	Herewith	:
For:	Rh(D)-BINDING PROTEINS AND	: Attorney Docket
	MAGNETICALLY ACTIVATED	: No. 9596-42U3
	CELL SORTING METHOD FOR	: (53893-5008-02)
	PRODUCTION THEREOF	:

PRELIMINARY AMENDMENT

Preliminary to the calculation of the filing fee and prior to the examination of the above identified application, please amend the application as follows:

In the Specification:

On page 1, immediately below the “title” please add the amended section submitted herewith.

On pages 7-11, please delete the section of the specification entitled “Brief Description of the Drawings” and substitute in place thereof the amended section submitted herewith.

In the Claims:

Please cancel claims 1-10 and 15-21, without prejudice.

Please amend claim 12 to more properly depend from claim 11, instead of claim 10 as originally filed. A marked up copy of claim 12 and a clean copy of amended claim 12 are submitted herewith on separate sheets.

Please add new claims 22-37, as submitted herewith on separate sheets.

REMARKS

Claims 11-14 and 22-37 are pending in the present application.

This application is a divisional of U.S. Application No. 09/240,274 (parent application). Claims 11-14 herein are the original nonelected claims of Group III designated in the Restriction Requirement dated March 16, 2000 in the parent application.

Claim 12 is amended to more properly depend from claim 11, instead of claim 10 as originally filed. Support for claim 12 is found throughout the specification, but is particularly found in the specification in Figures 1-16, Tables 1-4 (pages 35-42 and 102), and on pages 65-97 and 105-126 of the parent application.

Claims 22-37 are being added in the present application to more clearly set forth that which the Applicant regards as his invention. Support for new claims 22-37 is found in the specification in Figures 1-16, Tables 1-4 (pages 35-42 and 102), and on pages 65-97 and 105-126 of the parent application. Thus, no new matter has been added by way of these newly added claims.

Applicants respectfully request favorable examination of all of the pending claims in the application.

Respectfully submitted,

DONALD L. SIEGEL

MAY 4, 2001
(Date)

By:

Kathryn Doyle

Kathryn Doyle, Ph.D., J.D.

Registration No. 36317

MORGAN, LEWIS & BOCKIUS LLP

1701 Market Street

Philadelphia, PA 19103

Telephone: 215.963.4723

Facsimile: 215.963.5299

E-Mail: kdoyle@morganlewis.com

KD/rls

[illegible][illegible]

Marked Up Copy of Claim 12

12. The isolated DNA of claim [10] 11, having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 70-138 and 182-224.

11. The isolated DNA of claim 10, having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 70-138 and 182-224.

Clean Copy of Amended Claim 12

12. The isolated DNA of claim 11, having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 70-138 and 182-224.

11. The isolated DNA of claim 11, having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 70-138 and 182-224.

Newly Added Claims

22. The isolated DNA of claim 12, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 70-96 and 182-196.

23. The isolated DNA of claim 22, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 70-96.

24. The isolated DNA of claim 22, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 182-196.

25. The isolated DNA of claim 12, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 97-138 and 197-224.

26. The isolated DNA of claim 25, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 97-113.

27. The isolated DNA of claim 25, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 114-130.

28. The isolated DNA of claim 25, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 131-138 and 197-206.

29. The isolated DNA of claim 25, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 207-224.

30. The isolated DNA of claim 11, wherein said encoded protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-27 and 139-153.

31. The isolated DNA of claim 30, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 1-27.

32. The isolated DNA of claim 30, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 139-153.

33. The isolated DNA of claim 11, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 28-69 and 154-181.

34. The isolated DNA of claim 33, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 28-44.

35. The isolated DNA of claim 33, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 45-61.

36. The isolated DNA of claim 33, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 62-69 and 154-163.

37. The isolated DNA of claim 33, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 164-181.

Clean Copy of all Pending Claims for the Examiner's Convenience

11. An isolated DNA encoding a protein having an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 1-69 and 139-181.

12. The isolated DNA of claim 11, having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 70-138 and 182-224.

13. The isolated DNA of claim 12, being substantially purified.

14. An isolated DNA encoding a protein obtained by
generating a synthetic DNA library in a virus vector expressing said protein;
adding a magnetic label to cells expressing said antigen-bearing moiety;
incubating virus expressing said protein with said magnetically labeled cells in the presence of an excess of non-labeled cells which do not express said antigen-bearing moiety to form a mixture, wherein said virus binds to said magnetically labeled cells;
isolating virus bound cells from said mixture and obtaining DNA encoding said protein therefrom.

22. The isolated DNA of claim 12, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 70-96 and 182-196.

23. The isolated DNA of claim 22, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 70-96.

24. The isolated DNA of claim 22, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 182-196.

25. The isolated DNA of claim 12, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 97-138 and 197-224.

26. The isolated DNA of claim 25, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 97-113.

27. The isolated DNA of claim 25, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 114-130.

28. The isolated DNA of claim 25, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 131-138 and 197-206.

29. The isolated DNA of claim 25, wherein said DNA has a nucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 207-224.

30. The isolated DNA of claim 11, wherein said encoded protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-27 and 139-153.

31. The isolated DNA of claim 30, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 1-27.

32. The isolated DNA of claim 30, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 139-153.

33. The isolated DNA of claim 11, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 28-69 and 154-181.

34. The isolated DNA of claim 33, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 28-44.

35. The isolated DNA of claim 33, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 45-61.

36. The isolated DNA of claim 33, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 62-69 and 154-163.

37. The isolated DNA of claim 33, wherein said encoded protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 164-181.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Marked up Copy of the Brief Description of the Drawings

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagram of a strategy for cell-surface Fab-phage panning using magnetically-activated cell sorting.

5 **Figure 2** is a graph depicting cell-surface biotinylation of human RBCs.

Figure 3 is a series of graphs which validate the antigen-positive, antigen-negative cell separation procedure of the invention.

Figure 4 is an image of a microplate agglutination assay wherein anti-Rh(D) Fab/phage agglutination titer was measured.

10 **Figure 5** is an image of a microplate agglutination assay showing determination of Rh(D) binding epitope for selected anti-Rh(D) Fab/phage clones.

Figure 6 is an image depicting the use of Fab/phage antibodies in a gel card assay.

Figure 7 comprises Figures 7A and 7B. Figure 7A is a dendrogram
15 which depicts the relationship among the anti-Rh(D) heavy chains described herein in Example 2. The 28 unique heavy chain clones are organized by V_H family, V_H germline gene, and VDJ rearrangement. Each heavy chain clone is identified by a numeral preceded by a letter ("B" through "E") which denotes its germline gene. The 28 heavy chains comprised 12 distinct VDJ regions, designated VDJ1 - VDJ12.
20 Clones with identical VDJ joins putatively result from intra-clonal diversity of 12 original B lymphocytes. Figure 7B is an alignment of the CDR3 regions of the anti-Rh(D) heavy chains.

Figure 8 comprises Figures 8A, 8B, and 8C. Figure 8A, comprising
25 Figures 8A and 8A-1 through 8A-4, is an alignment of anti-Rh(D) heavy chains to their nearest germline V, D, and J genes. Also illustrated are the putative intermediate heavy chain sequences (Ca, Cb, Da, Db, Dc). The number of nucleotide differences from a germline V_H is tabulated to the right of each sequence. In general, D segments showed poor homology with known D genes so mutations were not scored in these regions. Replacement mutations are indicated with letters, silent mutations are
30 indicated as "*", identities are indicated as ".", and insertions are indicated as "-". Sequences derived from the 5' V_H primers used in library construction are indicated as

Marked up Copy of the Brief Description of the Drawings

">". Figure 8A is a map demonstrating how Figures 8A-1 to 8A-4 are arranged.

Figure 8B, comprising Figures 8B, 8B-1, and 8B-2 is an alignment of the four VH3 genes utilized by anti-Rh(D) heavy chains. Figure 8B is a map depicting the arrangement of Figures 8B-1 and 8B-2. Figure 8C is a dendrogram which depicts the relationship among human VH3 family germline genes, and illustrate relatedness of VH3-21, VH3-30, VH3-33, and VH3-30.3 and the surprising restriction in V_H gene usage. The VH3-30.5 gene is present in only certain haplotypes and is identical to VH3-30.

Figure 9 is an ontogenic tree of anti-Rh(D) heavy chains constructed using nucleotide alignment data. Circles represent isolated and sequenced clones, and diamonds represent putative intermediates. The number of nucleotide mutations from its germline V_H gene is indicated in parentheses below the clone name. The distance along the horizontal axis represents the degree of mutation (including J segments) within the constraints of the diagram.

Figure 10 comprises Figures 10A and 10B. Figure 10A, comprising Figures 10A and 10A-1 through 10A-4, is an alignment of anti-Rh(D) κ light chains to their nearest germline V and J genes, and indicates predominance of DPK-9 usage from the V _{κ} I family. Nomenclature for clones is similar to that for heavy chains but uses the letters "F" through "T". Figure 10A is a map depicting the arrangement of Figures 10A-1 through 10A-4. Figure 10B, comprising Figures 10B, 10B-1, and 10B-2 is an alignment of the four V _{κ} genes utilized by anti-Rh(D) light chains. Figure 10B is a map showing the arrangement of Figures 10B-1 and 10B-2. Symbols are the same as those used in Figure 8A.

Figure 11 comprises Figure 11A and 11B. Figure 11A, comprising Figures 11A and 11A-1 through 11A-4, is an alignment of anti-Rh(D) λ light chains to their nearest germline V and J genes. Figure 11A is a map depicting the arrangement of Figures 11A-1 through 11A-4. Figure 11B, comprising Figures 11B, 11B-1, and 11B-2, is an alignment of the 10 V _{λ} germline genes utilized, and illustrates the use of a diverse set of variable region genes derived from multiple families. However, all of the clones use the identical J _{λ} gene segment. Figure 11B is a map representing the arrangement of Figures 11B-1 and 11B-2. Nomenclature for the clones is similar to

Marked up Copy of the Brief Description of the Drawings

that for heavy chains but uses the letters "J" through "S". Symbols are the same as those used in Figure 8A.

Figure 12, comprising Figures 12A, 12B, and 12C, is a trio of graphs which depict comparisons of variable region gene family usage for anti-Rh(D)-specific clones and randomly-picked, non-Rh(D)-binding clones from original $\gamma_1\kappa$ and $\gamma_1\lambda$ non-selected libraries. [Lightly-hatched] Upwardly-angled bars reveal heterogeneity in V_H (Figure 12A), V_κ (Figure 12B), and V_λ (Figure 12C) family representation *before* selection for anti-Rh(D) specificity. Numbers above bars represent absolute number of clones in that group.

Figure 13 depicts the results of determinations of the Rh(D) binding epitope of anti-Rh(D) Fab/phage clones. The five different agglutination patterns obtained from screening all of the 53 Fab/phage clones are illustrated. The particular clones shown in Figure 13 are identified by their unique heavy chain/light chain pairings using the nomenclature defined in Figures 7, 10, and 11. For E1/M3, reactivity with additional Rh(D) variant cells is required to distinguish its specificity for epD3 from that for epD9. Inclusion of the category IVb cell permits the identification of a new epitope designated "epDX".

Figure 14, comprising Figures 14A and 14B, is matrix illustrating the genetic composition and epitope specificity of anti-Rh(D) antibodies. The horizontal axis represents the unique γ_1 heavy chains and the vertical axis represents the unique λ (Figure 14A) and κ (Figure 14B) light chains (based on amino acid sequence). A shaded pattern at the intersection of a heavy chain/light chain pair indicates the Rh(D) epitope specificity observed for that Fab/phage antibody. A few clones gave mixed patterns of reactivity as described herein. Although heavy chains D1, D15, D16, and D17 differ in nucleotide sequence, these chains have an identical amino acid sequence and thus comprise a single column. Similarly, heavy chains C5 and C8 and λ light chains K1 and K2 encode the same proteins. The pairings of these 28 heavy and 41 light chain nucleotide gene segments, which produced 53 unique Fab transcripts, encoded 43 different Fab proteins, as indicated in the matrix.

Figure 15, comprising Figures 15A, 15B, and 15C, depicts the results of inhibition studies performed using recombinant anti-Rh(D) antibodies. The figures

Marked up Copy of the Brief Description of the Drawings

show results of representative experiments demonstrating the mutual inhibition of antibodies directed at two different Rh(D) epitopes (in this example, epD3 and epD6/7, Figures 15A and 15C), but not between an Rh(D) antibody and an unrelated recombinant anti-RBC antibody (an anti-blood group B antibody, Figure 15B). In

5 Figure 15A, Rh(D)-positive RBCs were incubated with soluble Fabs only, phage-displayed Fabs only, or combinations of the two, as indicated. In Figure 15B, Rh(D)-positive RBCs that were blood group B were used. After washing, RBCs were resuspended in anti-M13 antibody and assessed for agglutination induced by phage-displayed Fabs. Soluble Fabs were used "full-strength" while Fab/phage preparations

10 were present in limiting amounts to increase the sensitivity of the inhibition assay, as described herein. In Figure 15C, mutual inhibition of epD3 and epD6/7 anti-Rh(D) antibodies was demonstrated with Rh(D)-positive RBCs, $\gamma_1\kappa$ and $\gamma_1\lambda$ soluble Fabs, and light chain isotype-specific antisera (see text for details). In these examples, the anti-epD3 and anti-epD6/7 antibodies were clones E1/M3 and D5/I3, respectively. The

15 anti-blood group B antibody was isolated from an IgG phage display library made from the splenic B cells of a blood group O donor.

Figure 16, comprising Figures 16A, 16B, and 16C, depict models for Rh(D) antigen/antibody binding. A conventional model (depicted in Figure 16A) and a model described herein (depicted in Figure 16B) for Rh(D) antigen/antibody binding predict

20 different combining sites and genetic relationships between antibodies. As depicted in Figure 16C, if antibodies directed at different Rh(D) epitopes are clonally related, then the expressed repertoire will differ between Rh(D)-negative and partial Rh(D) individuals.